General
Preferred name
ERIBULIN
Synonyms
B1939 mesylate ()
E7389 mesylate ()
ER-086526 mesylate ()
ERIBULIN MESYLATE ()
Halaven ()
Eribulin (mesylate) ()
B1939 (mesylate) ()
E7389 (mesylate) ()
ER-086526 (mesylate) ()
B1939 ()
E7389 ()
ER-086526 ()
E-7389 ()
Eribulin (as mesylate) ()
Eribulin monomethanesulfonate ()
Eribulin mesilate ()
P&D ID
PD052173
CAS
253128-41-5
441045-17-6
Tags
available
natural product
drug
Approved by
EMA
FDA
First approval
2010
Drug Status
investigational
approved
Drug indication
Breast cancer
Bladder cancer
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION A pan tubulin inhibitor which is a fully synthetic macrocyclic ketone analogue of the marine sponge natural product halichondrin B (a mitosis inhibitor). Marketed formulations may contain eribulin mesylate (PubChem CID 17755248). (GtoPdb)
Cell lines
4
Organisms
0
Compound Sets
19
AdooQ Bioactive Compound Library
A12804
ChEMBL Approved Drugs
CHEMBL1683590
CHEMBL1683544
ChEMBL Drugs
CHEMBL1683590
CHEMBL1683544
Concise Guide to Pharmacology 2017/18
6813
Concise Guide to Pharmacology 2019/20
6813
Concise Guide to Pharmacology 2021/22
6813
Concise Guide to Pharmacology 2023/24
6813
Drug Repurposing Hub
DrugBank
DB08871
DrugBank Approved Drugs
DB08871
DrugCentral
4171
DrugCentral Approved Drugs
4171
DrugMAP
DM1DX4Q
DM7JNTV
DrugMAP Approved Drugs
DM1DX4Q
DM7JNTV
Guide to Pharmacology
6813
MedChem Express Bioactive Compound Library
HY-13442
HY-13442A
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
LR24G6354G
ReFrame library
External IDs
44
Properties
(calculated by RDKit )
Molecular Weight
729.41
Hydrogen Bond Acceptors
12
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
10
Aromatic Ring Count
0
cLogP
3.44
TPSA
146.39
Fraction CSP3
0.88
Chiral centers
19.0
Largest ring
22.0
QED
0.41
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
breast cancer
MOA
microtubule inhibitor
Biosynthetic Origin
Polyketide
Therapeutic Indication
Anticancer
Pathway
Apoptosis
Cell Cycle/DNA Damage
cytoskeleton
Antibody-drug Conjugate/ADC Related
Target
Microtubule/Tubulin
ADC Cytotoxin
Source data